Journal of Microbiology Research
p-ISSN: 2166-5885 e-ISSN: 2166-5931
2016; 6(4): 69-74
doi:10.5923/j.microbiology.20160604.01
Amal H. Hassan 1, Hassan B. Elamin 2, Suliman M. Elsanousi 3, Abdel Moneim E. Sulieman 4, Mousa M. Alreshidi 4
1Department of Microbiology, Sudan Academy of Science, Khartoum2 (Northwest Ozone) –Khartoum, Sudan
2Department of Microbial Biotechnology-Commission on Biotechnology and Genetics Engineering, National Center for Research (NCR), Khartoum, Sudan
3Department of Veterinary Medicine, University of Khartoum, Bhary-Khartoum, Sudan
4Department of Biology, Faculty of Science, University of Hail, Hail, Kingdom of Saudi Arabia
Correspondence to: Abdel Moneim E. Sulieman , Department of Biology, Faculty of Science, University of Hail, Hail, Kingdom of Saudi Arabia.
Email: |
Copyright © 2016 Scientific & Academic Publishing. All Rights Reserved.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/
Diabetic foot infections are obviously spreading in hospital and facing unique challenge of successful treatment because of wide spread of resistant bacteria to many antibiotics. The clinical use of combination of antibiotics could be one of strategies to combat these resistant bacteria. Thus, basely depends on the microbial etiology and appropriate selective to antibiotics for combination. Using manual E-test method, Minimum inhibitory concentration (MIC) was determined susceptibility to individual antibiotics. Fractional inhibitory concentration index (FICI) was used to determine synergistic effects for combined antibiotics. Gentamicin susceptibility showed 100%, 40%, 80% and 60% of E.coli, Pseudomonas.spp, Staphylococcus aureus, and Proteus spp were sensitive, respectively. Ciprofloxacine showed 90%, 60%, 30% and 80 % resistant to E.coli, Pseudomonas spp, Staphylococcus aureus, and Proteu spp, respectively. Ceftriaxone showed 50%, 50%, 10%, and 80% resistant result against E.coli, Pseudomonas.spp, Staphylococcus aureus, and Proteus spp, respectively. Fractional inhibitory concentration index provided that 20%-40% Pseudomonas strains were synergistic to (gentamicin plus ciprofloxacin) and (gentamicin plus ceftriaxone), respectively. Since 100% of E.coli were antagonism to both combination. However, 80%-90% of Staphylococcus aureus, 70%-80% of Proteus spp showed indifferent effect to (gentamicin plus ciprofloxacin) and (gentamicin plus ceftriaxone), respectively.
Keywords: Diabetic foot infections, Antibiotics, Multidrug resistant bacteria, Antibiotic combination, Synergy
Cite this paper: Amal H. Hassan , Hassan B. Elamin , Suliman M. Elsanousi , Abdel Moneim E. Sulieman , Mousa M. Alreshidi , The Impact of Individual and Combined Antibiotics against Resistant Bacteria Isolated from Diabetic Foot Infection, Journal of Microbiology Research, Vol. 6 No. 4, 2016, pp. 69-74. doi: 10.5923/j.microbiology.20160604.01.
|
Figure 1. Sensitivity pattern of combined Gentamicin/Ciprofloxacin on the four most common bacterial isolates from diabetic foot wounds, Omdurman Military Hospital, Sudan April-May 2015 |
Figure 2. Sensitivity pattern of combined Gentamicin/Ceftriaxone on the four most common bacterial isolates from diabetic foot wounds, Omdurman Military Hospital, Sudan April-May 2015 |
[1] | Lipsky, B. A. et al. (2012). Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54, e132–73 (2012). |
[2] | Crouzet, J., Lavigne, J. P., Richard, J. L. and Sotto, A (2011). Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int. J. Infect. Dis. 15, e601–10 (2011). |
[3] | Neidell, M. J. et al. (2012). Costs of healthcare-and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin. Infect. Dis. 55, 807–815 (2012). |
[4] | DiazGranados, C. A., Cardo, D. M. and McGowan, J. E. (2008). Antimicrobial resistance: international control strategies, with a focus on limited-resource settings. International Journal of Antimicrobial Agents 32, 1–9 (2008). |
[5] | Woods, D. E., Schaffer, M. S., Rabin, H. R., Campbell, G. D. and Sokol, P. A. (1986). Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J. Clin. Microbiol. 24, 260–4 (1986). |
[6] | Leekha, S., Terrell, C. L. & Edson, R. S. (2011). General principles of antimicrobial therapy. Mayo Clin. Proc. 86, 156–67 (2011). |
[7] | Windows, M. et al. (2014). No Title No Title. Uma ética para quantos? XXXIII, 81–87 (2014). |
[8] | Clsi. (3013). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Clinical and Laboratory Standards Institute 32, (2013). |
[9] | Meletiadis, J., Pournaras, S., Roilides, E. and Walsh, T. J. (2010). Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumi. Antimicrob. Agents Chemother. 54, 602–9 (2010). |
[10] | Levy, S. B. (2002). Factors impacting on the problem of antibiotic resistance. J. Antimicrob. Chemother. 49, 25–30 (2002). |
[11] | Kibret, M. & Abera, B. (2011). Antimicrobial susceptibility patterns of E. coli from clinical sources in northeast Ethiopia. Afr. Health Sci. 11 Suppl 1, S40–5 (2011). |
[12] | Lowman, W., Aithma, N., Duse, A. G. and Mer, M. (2012). Comparative MIC evaluation of a generic ceftriaxone by both microdilution on clinically relevant isolates from an academic hospital complex in South Africa. South African Medical Journal 102, 102–103 (2012). |
[13] | Masood, S. H. and Aslam, N. (2010). In Vitro Susceptibility Test of Different Clinical Isolates against Ceftriaxone. Oman Med. J. 25, 199–202 (2010). |
[14] | Anguzu, J. R. and Olila, D. (2007). Drug sensitivity patterns of bacterial isolates from septic post-operative wounds in a regional referral hospital in Uganda. Afr. Health Sci. 7, 148–54 (2007). |
[15] | Akhtar, N., Alqurashi, A. M. and Abu Twibah, M. (2010). In vitro ciprofloxacin resistance profiles among gram-negative bacteria isolated from clinical specimens in a teaching hospital. J. Pak. Med. Assoc. 60, 625–7 (2010). |
[16] | Bahashwan, S. A. & Shafey, H. M. El. (2013). Antimicrobial resistance patterns of proteus isolates from clinical specimens. Eur. Sci. J. 9, 1857–788 (2013). |
[17] | Nwankwo, E. O. and Nasiru, M. S. (2011). Antibiotic sensitivity pattern of Staphylococcus aureus from clinical isolates in a tertiary health institution in Kano, Northwestern Nigeria. Pan Afr. Med. J. 8, 4 (2011). |
[18] | Salem-bekhit, M. M. Phenotypic and Genotypic Characterization of Nosocomial Isolates of Staphylococcus aureus with Reference to Methicillin Resistance. 13, 1239–1246 (2014). |
[19] | Samuelsen O, Haukland HH, Kahl BC, von Eiff C, Proctor RA, Ulvatne H, et al. (2005). Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J Antimicrob Chemother. 2005; 56(6): 1126-9. |
[20] | Onyango LA, Dunstan RH, Gottfries J, von Eiff C, Roberts TK. (2012). Effect of Low Temperature on Growth and Ultra-Structure of Staphylococcus spp. PLoS One. 2012; 7(1): e29031. PubMed Central PMCID: PMC3265459. |
[21] | Alreshidi MM, Dunstan HR, Roberts TK, Onyango LA. Staphylococcal phenomics: metabolomic and proteomic responses to environmental stressors. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education. 1. Badajoz, Spain Formatex Research Center; 2013. p. 690-701. |
[22] | Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. (2004). Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol. 2006;4(4):295-305. doi: 10.1038/nrmicro1384. PubMed PMID: 16541137. |
[23] | Cervantes-Garcia E, Garcia-Gonzalez R, Reyes-Torres A, Resendiz-Albor AA, Salazar-Schettino PM. Staphylococcus aureus small colony variants in diabetic foot infections. Diabet Foot Ankle. 2015;6:26431. doi: 10.3402/dfa.v6.26431. PubMed PMID: 25787018; PubMed Central PMCID: PMC4365137. |
[24] | Kriegeskorte A, Konig S, Sander G, Pirkl A, Mahabir E, Proctor RA, et al. Small colony variants of Staphylococcus aureus reveal distinct protein profiles. Proteomics. 2011;11(12):2476-90. doi: DOI 10.1002/pmic.201000796. PubMed PMID: ISI:000292832500009. |
[25] | Alreshidi MM, Dunstan RH, Macdonald MM, Smith ND, Gottfries J, Roberts TK. Metabolomic and proteomic responses of Staphylococcus aureus to prolonged cold stress. J Proteomics. 2015;121:44-55. doi: 10.1016/j.jprot.2015.03.010. PubMed PMID: 25782752. |
[26] | Alreshidi MM, Dunstan RH, Gottfries J, Macdonald MM, Crompton MJ, Ang CS, et al. (2016). Changes in the Cytoplasmic Composition of Amino Acids and Proteins Observed in Staphylococcus aureus during Growth under Variable Growth Conditions Representative of the Human Wound Site. PLoS One. 2016;11(7):e0159662. doi: 10.1371/journal.pone.0159662. PubMed PMID: 27442022; PubMed Central PMCID: PMC4956324. |
[27] | Yasmin, F., Akhtar, N. and Hameed, A. (2013). Report: In vitro synergistic Effect of Ciprofloxacin with Aminoglycosides against Multidrug resistant-Pseudomonas aeruginosa. Pak. J. Pharm. Sci. 26, 1041–4 (2013). |
[28] | Angehrn, P. (1983). In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. 2, 489–95 (1983). |
[29] | Dickgiesser, N., in der Stroth, S. and Wundt, W. (1986). Synergism of ciprofloxacin with beta-lactam antibiotics, gentamicin, minocycline and pipemidic acid]. Infection 14, 82–5 (1986). |
[30] | Weiss, D., Trautmann, M., Wagner, J., Borner, K. and Hahn, H. (1986). Ciprofloxacin: a comparative evaluation of its bactericidal activity in human serum against four enterobacterial species. Drugs Exp. Clin. Res. 12, 889–94 (1986). |